Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease

Satoshi Takanashi, Naoshi Nishina, Maho Nakazawa, Yuko Kaneko, Tsutomu Takeuchi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD). METHODS: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups. RESULTS: Among 110 patients enrolled, 75 (68%) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse. CONCLUSION: Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.

Original languageEnglish
Pages (from-to)1034-1039
Number of pages6
JournalRheumatology (Oxford, England)
Volume58
Issue number6
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Myositis
Interstitial Lung Diseases
Serum
Recurrence
Biomarkers
Lung Diseases

Keywords

  • biomarker
  • clinically amyopathic DM
  • DM
  • interstitial lung disease
  • Krebs von den Lungen-6
  • myositis
  • PM
  • relapse

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. / Takanashi, Satoshi; Nishina, Naoshi; Nakazawa, Maho; Kaneko, Yuko; Takeuchi, Tsutomu.

In: Rheumatology (Oxford, England), Vol. 58, No. 6, 01.06.2019, p. 1034-1039.

Research output: Contribution to journalArticle

@article{e1270f858d7745b88374ebe65156fa41,
title = "Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease",
abstract = "OBJECTIVE: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD). METHODS: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups. RESULTS: Among 110 patients enrolled, 75 (68{\%}) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse. CONCLUSION: Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.",
keywords = "biomarker, clinically amyopathic DM, DM, interstitial lung disease, Krebs von den Lungen-6, myositis, PM, relapse",
author = "Satoshi Takanashi and Naoshi Nishina and Maho Nakazawa and Yuko Kaneko and Tsutomu Takeuchi",
year = "2019",
month = "6",
day = "1",
doi = "10.1093/rheumatology/key420",
language = "English",
volume = "58",
pages = "1034--1039",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease

AU - Takanashi, Satoshi

AU - Nishina, Naoshi

AU - Nakazawa, Maho

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

PY - 2019/6/1

Y1 - 2019/6/1

N2 - OBJECTIVE: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD). METHODS: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups. RESULTS: Among 110 patients enrolled, 75 (68%) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse. CONCLUSION: Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.

AB - OBJECTIVE: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD). METHODS: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups. RESULTS: Among 110 patients enrolled, 75 (68%) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse. CONCLUSION: Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.

KW - biomarker

KW - clinically amyopathic DM

KW - DM

KW - interstitial lung disease

KW - Krebs von den Lungen-6

KW - myositis

KW - PM

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85066496367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066496367&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/key420

DO - 10.1093/rheumatology/key420

M3 - Article

C2 - 30624752

AN - SCOPUS:85066496367

VL - 58

SP - 1034

EP - 1039

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 6

ER -